averaged and inhibition of total specific binding is calculated total specific binding total u2212 nonspecific in some cases the amounts of unlabeled drugs is varied and total displacement curves of binding are carried out data are converted to ki 39 s results for compounds of this invention are listed in table 2 the compounds of general formula i may be administered orally topically parenterally by inhalation or spray or rectally in dosage unit formulations containing conventional non toxic pharmaceutically acceptable carriers adjuvants and vehicles the term parenteral as used herein includes subcutaneous injections intravenous intramuscular intrasternal injection or infusion techniques in addition there is provided a pharmaceutical formulation comprising a compound of general formula i and a pharmaceutically acceptable carrier one or more compounds of general formula i may be present in association with one or more non toxic pharmaceutically acceptable carriers and or diluents and or adjuvants and if desired other active ingredients the pharmaceutical compositions containing compounds of general formula i may be in a form suitable for oral use for example as tablets troches lozenges aqueous or oily suspensions dispersible powders or granules emulsion hard or soft capsules or syrups or elixirs compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents flavoring agents coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.